TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04261868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: New treatment for amblyopia therapy using playing games

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patching
Study: NCT03344133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 4-week moderate intensity exercise programme
Study: NCT03771898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP611
Description: Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
Study: NCT02126397

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polyps resection with Laser Diode
Description: resection of endometrial polyps by hysteroscopy without anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polyps resection with bipolar electrode
Study: NCT01496638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of coronary stent in bifurcation lesion
Description: Implantation of coronary stent in bifurcation lesion with no side branch treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of coronary stent in bifurcation lesion
Description: Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
Study: NCT03523910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) with exercise
Description: MRI scan with a novel exercise device.
Study: NCT03615001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDOC NXT
Description: Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
Study: NCT04472871

Intervention type: DEVICE
Intervention: Left atrial appendage closure
Description: The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.

Intervention type: DEVICE
Intervention: Left atrial appendage closure
Description: The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
Study: NCT05114044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
Study: NCT02244931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E.Motion© assisting device
Description: E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard manual Wheelchair
Description: Standard manual Wheelchair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard manual Wheelchair
Description: Standard manual Wheelchair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard manual Wheelchair
Description: Standard manual Wheelchair
Study: NCT01301482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture
Description: Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
Study: NCT02096822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated tucking + non-nutritive sucking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-nutritive sucking
Study: NCT04204031

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Presentation of the adherence record
Description: Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
Study: NCT03669016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face group-based mindfulness
Description: An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based mindfulness
Description: An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
Study: NCT01956487

Intervention type: DRUG
Group type: OTHER
Intervention: Propafenone
Description: Comparison of drug from 2 manufacturing sites
Study: NCT04733248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping group
Description: * HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit.
Study: NCT01969929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20G Vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23G vitrectomy
Study: NCT02310269

Intervention type: DRUG
Intervention: Pasireotide

Intervention type: DRUG
Intervention: Pasireotide
Study: NCT03487133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib/dexamethasone
Description: Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none
Study: NCT00734032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB480848 40mg EC Tablet
Description: 1 tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB480848 80mg EC Tablet
Description: 1 tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB480848 160mg EC Tablet
Description: 1 tablet once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB480848 Placebo Tablet
Description: 1 tablet once a day
Study: NCT02711098

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory biomarkers dosage Hypothermia Arm
Description: There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory biomarkers dosage Normothermia Arm
Description: There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
Study: NCT00977444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kondrium
Description: intraarticular injections once month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kondrium f
Description: intraarticular injections once month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl prednisolone (corticosteroid)
Description: intraarticular injections once month
Study: NCT01927614

Intervention type: RADIATION
Intervention: Cardiac CT
Description: A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus.
Study: NCT00309452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: once per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: as needed
Study: NCT00660673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Description: LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Description: Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
Study: NCT00309452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications
Description: Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG
Description: Multi-Family psychoeducation Group based on the model published by McFarlane et al.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive case management
Description: Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual in the community
Description: Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
Study: NCT00917358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon alfa-2a 135 ug/week for 24 weeks
Study: NCT04815057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
Study: NCT00024466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Study: NCT02442466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin Receptor B inhibitor BQ788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBS
Study: NCT00660673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Description: All participants previously had a PEG-J placed in one of the prior LCIG studies.
Study: NCT03023787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Study: NCT04733248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching group
Description: * HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit
Study: NCT00717782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of botulinum toxin
Description: Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
Study: NCT00627185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered continuing professional development
Description: Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
Study: NCT03738137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narotrend
Description: Narcotrend motoring
Study: NCT00627185

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention arm
Study: NCT03738137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: Bispectral index monitoring
Study: NCT00717782

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: injection of saline
Description: Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
Study: NCT00697970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg formulated with different concentrations of MPL and Aluminium Salts
Description: Intramuscular injection, 3 doses
Study: NCT03738137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil is applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil is applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil is applied.
Study: NCT03738137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Topical Anesthesia
Study: NCT03780543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Description: Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Description: Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Description: Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
Study: NCT03505190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
Study: NCT03738137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Topical Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Topical Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Topical Anesthesia
Study: NCT03738137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is applied.
Study: NCT04414878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow™ II Transcatheter Aortic Valve System
Description: VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
Study: NCT02763904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intensive nutritional counseling
Description: Dietary counseling + energy-dense oral nutritional supplements since admission

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
Study: NCT02012166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 10 mg
Description: MK-0893 10 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 10 mg
Description: MK-0893 10 mg administered orally in 240 mL of water
Study: NCT05349838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Description: Daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Description: Daily oral tablet
Study: NCT00697970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg formulated with different concentrations of MPL and Aluminium Salts
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg formulated with different concentrations of MPL and Aluminium Salts
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses
Study: NCT04170062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
Study: NCT02310516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: preoperative adequate explanations about awake surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no preoperative explanation
Study: NCT03225014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Recovery Performance Wave Therapy
Description: ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.